Literature DB >> 17181451

The side effects of the prostaglandin analogues.

Gábor Holló1.   

Abstract

In the last decade topically applied prostaglandin F2alpha analogues (bimatoprost, latanoprost, travoprost and unoprostone) have become widely used as a means to reduce elevated intraocular pressure in patients with glaucoma and ocular hypertension. These molecules all have similar side-effect profiles, which include both side effects that occur frequently (e.g., conjunctiva hyperaemia, increase of iris pigmentation and eyelash changes) and rare adverse reactions (e.g., periocular pigmentation, damage to the blood-aqueous barrier and cystoid macular oedema). Conjunctiva hyperaemia, eyelash changes and cystoid macular oedema are reversible, but certain other side effects, such as increased iris pigmentation, are not. However, the systemic side-effect profile is favourable for all the prostaglandin analogues, and some of the local side effects are only of cosmetic significance. Numerous clinical studies suggest that discontinuing treatment with prostaglandin analogues on account of their side effects is rare in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17181451     DOI: 10.1517/14740338.6.1.45

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  48 in total

1.  Incidence of deepening of the upper eyelid sulcus after switching from latanoprost to bimatoprost.

Authors:  Makoto Aihara; Shiroaki Shirato; Rei Sakata
Journal:  Jpn J Ophthalmol       Date:  2011-09-28       Impact factor: 2.447

Review 2.  Targeted Ocular Drug Delivery with Pharmacokinetic/Pharmacodynamic Considerations.

Authors:  Jie Shen; Guang Wei Lu; Patrick Hughes
Journal:  Pharm Res       Date:  2018-09-25       Impact factor: 4.200

3.  Effectiveness of the ICare rebound tonometer in patients with overestimated intraocular pressure due to tight orbit syndrome.

Authors:  You Kyung Lee; Y K Lee; Ji Young Lee; J Y Lee; Jung Il Moon; J I Moon; Myoung Hee Park; M H Park
Journal:  Jpn J Ophthalmol       Date:  2014-08-29       Impact factor: 2.447

4.  Discovery to Launch of Anti-allergy (Emadine; Patanol/Pataday/Pazeo) and Anti-glaucoma (Travatan; Simbrinza) Ocular Drugs, and Generation of Novel Pharmacological Tools Such as AL-8810.

Authors:  Najam A Sharif
Journal:  ACS Pharmacol Transl Sci       Date:  2020-11-05

5.  In vitro study of antiadipogenic profile of latanoprost, travoprost, bimatoprost, and tafluprost in human orbital preadiopocytes.

Authors:  Hee Young Choi; Ji Eun Lee; Ji Woong Lee; Hyun Jun Park; Ji Eun Lee; Jae Ho Jung
Journal:  J Ocul Pharmacol Ther       Date:  2011-11-22       Impact factor: 2.671

6.  Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients.

Authors:  M Figus; M Nardi; P Piaggi; M Sartini; G Guidi; L Martini; S Lazzeri
Journal:  Eye (Lond)       Date:  2014-01-17       Impact factor: 3.775

7.  Travoprost in the management of open-angle glaucoma and ocular hypertension.

Authors:  Philippe Denis; David Covert; Anthony Realini
Journal:  Clin Ophthalmol       Date:  2007-03

8.  Prolonging the in vivo residence time of prostaglandin E(1) with biodegradable nanoparticles.

Authors:  Tsutomu Ishihara; Miyuki Takahashi; Megumu Higaki; Mitsuko Takenaga; Tohru Mizushima; Yutaka Mizushima
Journal:  Pharm Res       Date:  2008-02-22       Impact factor: 4.200

9.  Antiglaucoma drugs: The role of preservative-free formulations.

Authors:  Alessandro Bagnis; Marina Papadia; Riccardo Scotto; Carlo E Traverso
Journal:  Saudi J Ophthalmol       Date:  2011-08-28

10.  Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis.

Authors:  Oghenowede Eyawo; Jean Nachega; Pierre Lefebvre; David Meyer; Beth Rachlis; Chia-Wen Lee; Steven Kelly; Edward Mills
Journal:  Clin Ophthalmol       Date:  2009-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.